INTRODUCTION
MS is a chronic disease of the central nervous system characterised by multi-focal inflammatory demyelinating lesions. The number and distribution of the T2-hyperintense lesions (WML) in white matter found with magnetic resonance imaging (MRI) have a central role in the diagnosis of MS, but explain little of the future risk of disability progression (1, 2) .
The low predictive significance of WML may partially be explained by more diffuse inflammatory neuropathology evident in the white matter post mortem that appears normal on conventional MRI (3) . Individual WML in the same brain and at different stages of disease also can have different neuropathological characteristics not well distinguished by MRI (4) . Innate immune responses involving pro-inflammatory microglia are associated with both the focal and diffuse inflammation (5-8) .
The 18 kDa mitochondrial TSPO is highly expressed in activated microglia (9).
Clinical studies using the first generation TSPO PET radioligand 11C-PK11195 reported higher global brain uptake in MS than healthy volunteers (10). WML showed variably increased or decreased TSPO radioligand uptake (11, 12) . Recent studies have highlighted more diffuse uptake (13, 14) . However, a challenge to interpretation of the literature overall is the use of different radioligands and different analytical methods.
In the present study, we have assessed in vivo PET TSPO radioligand binding in MS patients with 11C-PBR28 and re-analysed previously published data obtained with 
MATERIALS AND METHODS

Subjects
The study protocol was approved by the West Bromley Research Ethics Committee (Ref No. 14/LO/0445). All subjects signed a written informed consent. MS was diagnosed according to the revised McDonald criteria (2010)(19). Subjects had a Expanded Disability Status Scale (EDSS) score < 7.0 and none were treated with steroids or had a clinical relapse within 3 months of scanning. MS patients and healthy volunteers (HV) scanned with 18F-PBR111 and HV scanned with 11C-PBR28 were described previously (13, 15, 17) . 
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Imaging Methods
MRI Scanning
MRI scans were performed on a 3 Tesla Trio scanner (11C-PBR28 cohort) or a 3 Tesla Verio scanner (11C-PBR28 cohort) (both from Siemens Healthcare, Erlangen Germany). Volumetric T1-weighted images were acquired for all subjects using a 1 mm isotropic resolution, before and 5 minutes after intravenous gadolinium chelate (Dotarem®) administration. Volumetric T2-weighted images were acquired using a 1mm isotropic resolution.
MRI Image Processing and Definition of Regions of Interest
WML were segmented on the T2 image using Jim (Xinapse Systems version 7). The WML mask was used for lesion-filling the T1 image before segmentation into white matter, grey matter and cerebrospinal fluid using FMRIB Software Library tools (22) .
Peri-lesional masks were generated by dilating the WML mask in 3D by 6mm and subtracting the WML mask. A NAWM mask was created by subtracting the dilated WML mask from the total white matter mask and eroding by by 3mm. The Clinical (23) .
PET Scanning and Radioligand Synthesis
PET scanning (Discovery RX PET/CT scanner) was performed with a trans-axial resolution of 5.0 mm, and a radial resolution of 5.1 mm. 11C-PBR28 or [
were injected as an intravenous bolus over approximately 20 s at the start of a 90 min and 120 min dynamic PET acquisitions, respectively (15, 21) .
Radiosynthesis and quality control were performed on site also as previously described, with radiochemical purities of > 95% (15, 21) .
PET Image and Kinetic Analysis
T1 images, NAWM, WML, caudate and thalamus masks and reconstructed dynamic PET scans were used as inputs for the Molecular Imaging and Kinetic Analysis Toolbox software (www.miakat.org) for kinetic analysis of PET data. PET images were motion corrected using SPM5 (Wellcome Trust Centre for Neuroimaging, http://www.fil.ion.ucl.ac.uk/spm) for frame-by-frame rigid realignment .
Standardized uptake values (SUV) were calculated from the time-activity curves between 60 -90 minutes for 11C-PBR28 and 90-120 minutes for [ Reference based PET analyses enhances patient tolerance as arterial blood sampling is not needed. Here we used the Logan graphical reference method (24) to estimate regional brain DVR using the caudate time activity curve as the reference tissue input (25) . Most previous MS studies also have used reference based methods (10-12,14,26-28). We and others have confirmed that reference based methods are strongly correlated with direct estimates of volume of distribution, V T (13, 26, 27, 29) .
While the reference tissue ideally is does not show specific (displaceable) ligand, TSPO which is expressed ubiquitously in the brain (29) . Reference methods for TSPO have differed by the choice of reference tissue, broadly distinguished by those that use an individually variable reference, defined on the basis of appearing most similar to the behaviour expected for the healthy brain (26, 27) and those that are anatomically defined and selected identical for all subjects (12, 28) . We chose to use the latter, as the interpretation and assumptions of lack of inter-patient heterogeneity are more directly tested.
All of these approaches technically define a "pseudo-reference" region and vary in dynamic range or sensitivity by the extent and variance in radioligand uptake in the region selected. We used the caudate nucleus because can be defined reliably using automated segmentation methods, show relatively lower levels of microglial activation in MS patients and TSPO binding relative to other brain regions (21). We 0.66 ± 0.13 for HV, p=0.26). We directly tested the accuracy of the relative uptakes estimated from the DVR calculated with the caudate "pseudo-reference" region and the ratio of SUV in brain regions to the SUV in caudate was strongly correlated with the DVR measure for MS and HV for both radioligands (Supplemental Fig. 1 ).
Individual Lesion Analysis and Classification
For the final analysis, WML with volume > 8 mm 3 were sampled to match the fullwidth half-maximum of the PET scanner of approximately 5 mm. Based on earlier results (30) and new test-retest PET data (Supplemental Fig. 2 ), four classes of lesions were identified based on the presence of differences in DVR > 5% in the lesion core and in the peri-lesional volume relative to surrounding NAWM: high uptake relative to surrounding NAWM ("active lesions"); highest uptake in the peri-lesional volume ("peripherally active lesions"); uptake similar to the NAWM ("undifferentiated lesions"); low uptake ("inactive lesions"). Statistical analyses were performed using SPSS software (IBM, SPSS v22). The oneway analysis of variance was used to analyse the variance of between subjects factors. Homogeneity of variance was confirmed with Levene's test of equal variances. Post hoc analysis to assess differences between group means was performed with correction for multiple comparisons (Tukey's honest significant difference). Descriptive statistics were reported as mean ± standard deviation, unless otherwise stated. For correlational analyses, the Spearman's correlation coefficient was calculated, unless otherwise stated. A p-value (Bonferroni corrected for multiple comparsions) of less than 0.05 was considered statistically significant.
Statistical Analyses
RESULTS
Demographic and clinical characteristics of study participants are summarised in
Supplemental Tables 1 and 2 . Data from 24 MS patients and 20 HV scanned with 11C-PBR28 and from 10 MS patients and 10 HV scanned with 18F-PBR111are included.
The MS patients studied with the two radioligands were well matched for age, sex, EDSS and disease duration. However, approximately 30% of the 11C-PBR28 PET cohort had SPMS, while all of those in the 18F-PBR111PET group had RRMS.
Brain TSPO Radioligand Uptake
There were significant differences in the 11C-PBR28 DVR across brain regions for the MS and HV (one-way analysis of variance, p=4x10 -19 ). Uptake was highest in the thalamus; the thalamic 11C-PBR28 DVR in patients with MS (mean ± s.d., 1.52 ± 0.04) by King's College London on April 23, 2017. For personal use only. jnm.snmjournals.org Downloaded from was higher than in HV (1.39 ±0.05, p=0.03). The DVR of NAWM (1.17 ± 0.04) in the MS patients also was higher than in the white matter of HV (1.02 ± 0.05, p=0.02; Fig.   1A ). 11C-PBR28 uptake in the NAWM was greater for patients than the mean uptake across WML (1.03 ± 0.04, p=0.03).
Our re-analysis of the smaller 18F-PBR111dataset found similar trends.
Differences in DVR again were found between the MS and HV groups (p=1x10 -6 ). 18F-PBR111DVR in NAWM of the MS patients (1.27 ± 0.04) was greater than that in the HV white matter (1.13 ± 0.04, p=0.02; Fig. 1B ) . The mean thalamic DVR for MS patients (1.50 ± 0.04) was greater than for HV (1.41 ± 0.04), although not statistically significantly so (p=0.08). We did not find differences between the mean DVR in the NAWM and WML (p=0.93).
Baseline disability (EDSS) was not correlated with DVR in any brain region studied for either radioligand.
TSPO Binding in NAWM and Individual WML of MS Patients
We evaluated differences in white matter DVR between subjects (Fig. 2) . The ranges in DVR for 11C-PBR28 (median, 1.10, range 0.80-1.85, Supplemental showed a wide variation in DVR (Fig. 2 ). There was a strong correlation between the median WML DVR and NAWM DVR (Spearman's ρ = 0.94 for both radioligands; p= 4x10 -11 (11C-PBR28) or p= 1x10 -4 (18F-PBR111)) (Fig. 3) .
We found only two gadolinium enhancing lesions in scans from the MS patients.
The gadolinium enhancing lesions (one in a patient scanned with 11C-PBR28 and one with 18F-PBR111) had high DVR (1.81 and 1.19, respectively), but not the highest DVR of lesions within those subjects (Fig. 2, A22 and B3).
Classification of Individual Lesions Based on Relative TSPO Uptake
We pooled data from the 11C-PBR28 and 18F-PBR111cohorts after classification of 
DISCUSSION
We found similar relative differences between MS patients and HV using both TSPO PET radioligands. Both were associated with heterogeneity of TSPO tracer uptake in NAWM and between lesions in the MS patients. The strong correlation between the NAWM and WML TSPO uptake for individual patients suggests that these measures both reflect the same individually variable, innate inflammatory phenotype. The differences in inflammatory activity were not well reflected in the conventional MRI measures; gadolinium enhancement identified only two lesions out of a total of 558 lesions with increased TSPO radioligand uptake (Fig. 2) . We found that lesions with diffusely high TSPO radioligand uptake (which we have called "active" lesions) can be found in all disease stages and treatment groups. Neuropathology studies and in vivo PET TSPO imaging both provide evidence for a diffuse inflammatory process in white matter. This is associated with evidence of neuronal injury (18,31,32) . Focal clusters or nodules of white matter microglial activation may precede the formation of WML (33) . Consistent with these observations (and prior studies using 11C-PK11195), we found that TSPO binding was higher in the NAWM than in the white matter of HV (11, 12, 14) . Increased uptake in the NAWM of patients with clinically isolated syndrome is associated with early development of clinically definite MS (34).
We found a heterogeneous pattern of microglial activation in WML relative to the NAWM both between and within MS patients. This heterogeneity is consistent with post mortem histopathology, which shows variable microglial activation between lesions (6,35). Prior studies also have shown variable TSPO radioligand uptake within lesions relative to NAWM (11, 12) . What has not been noted before is the strong correlation between the TSPO binding in NAWM and in WML. This suggests that patients are better described in terms of a global inflammatory state of their white matter rather than by individual lesion activity. Extending the earlier observations with clinically isolated syndrome (34), measures of this global white matter innate inflammatory activity may be predictive of the short term disease course generally for patients with MS.
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We classified individual lesions into four different classes based on the patterns of TSPO radioligand uptake relative to that in the surrounding NAWM. The classification is similar conceptually to that used histopathologically for WML in MS brains: both rely on differences in distributions of activated microglia (35) . In our study, we identified all four of these lesion types in vivo in all disease stages. There were a higher proportion of inactive lesions in patients with longer disease duration and with SPMS than in RRMS. These findings in vivo are reflected in a recent study of brains post mortem, where histopathologically defined inactive lesions are more common with SPMS and longer disease duration (5). However, we also found that TSPO PET "active" lesions were more common in brains of patients with SPMS than those from patients with RRMS. Unexpectedly, we found active lesions even in patients receiving either of two of the most efficacious pharmacological immunomodulators (alemtuzimab and nataluzimab).
These data thus provide further evidence for substantial persistent innate inflammatory activity in SPMS (10). They also suggest that current treatments classed as highly efficacious based on suppression of T2 hyperintense lesion activity do not suppress microglial activity fully. Persistent, pro-inflammatory microglia could explain the progression of neurodegenerative changes reflected as brain atrophy or disability progression that are seen in some patients (35) . However, alternative microglial activation phenotypes also can contribute to reparative processes (36) . Previous TSPO PET studies have reported positive correlations between disability (EDSS) and TSPO ligand uptake (10,13), but we did not observe this with either of our two patient groups. This may be related to sample sizes, as neither study was powered for this outcome. The lack of correlation between disability and TSPO uptake could reflect limitations of a cross-section design: disability measures reflect the summary impact of relevant injury to date, whereas the PET measures are determined by inflammatory activity only at the time of the scan. Insensitivity of EDSS to all relevant dimensions of disability could also contribute (38) . Finally, quantifying TSPO binding using a pseudo-reference region method may have led to an underestimation of regional radioligand uptake (35) . The reduced dynamic range of the reference-based measure could limit discrimination of differences between tissues, despite the gain in precision. We also did not have repeat examinations on all subjects, so we had to define meaningful differences in DVR based on a "hard threshold" estimated from independent test-retest estimates.
In vitro, ex vivo and in silico data indicate that 11C-PBR28 has higher binding affinity for TSPO and higher displaceable to nondisplaceable binding compared with 18F-PBR111, when matched for TSPO binding status (39) . A study using a TSPO agonist (XBD173) to block binding of 11C-PBR28 in healthy volunteers directly confirmed estimates of relatively high displaceable (specific) binding for this ligand Together, these factors suggest that for many applications, 11C-PBR28 is a preferable radioligand. However, the longer half-life of 18F-PBR111 (110 minutes) than 11C-PBR28 (20 minutes) makes the former more practical for transportation between sites without the need for having an on site cyclotron to produce the radioligand. Further work needs to be done, for instance with blocking studies of 18F-PBR111, to characterise the in vivo binding characteristics of both radioligands, but, depending on manufacturer/supply arrangements, 18F-PBR111 could have advantages at some sites.
CONCLUSION
Our report provides further evidence for continuing inflammation and heterogeneity in the innate immune inflammatory activity of individual lesions and NAWM of patients with MS that is not captured by conventional MRI. Our results highlight that gadolinium contrast enhancement underestimates the total inflammatory activity. We also found that the overall innate inflammatory activity was not appreciably lower in patients with RRMS relative to SPMS. We hypothesise that this inflammation contributes to determining the prognosis of individual patients. PET may provide a pharmacodynamic marker for treatments targeting this 
